Drug Search Results
More Filters [+]

Ciclesonide

Alternative Names: ciclesonide, omnaris, alvesco, zetonna
Latest Update: 2024-03-18
Latest Update Note: Clinical Trial Update

Product Description

Ciclesonide is used to help prevent the symptoms of asthma. When used regularly every day, inhaled ciclesonide decreases the number and severity of asthma attacks. However, it will not relieve an asthma attack that has already started. Ciclesonide is a corticosteroid or steroid (cortisone-like medicine). It works by preventing inflammation (swelling) in the lungs, which makes the asthma attack less severe . (Sourced from: https://www.mayoclinic.org/drugs-supplements/ciclesonide-inhalation-route/side-effects/drg-20071477?p=1)

Mechanisms of Action: GR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical,Nasal,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Rhinitis | Rhinitis, Allergic | Rhinitis, Allergic, Seasonal | Spasm | Asthma

Known Adverse Events: Headache | Epistaxis | Back Pain | Pain Unspecified | Nasopharyngitis | Pharyngitis | Arthralgia | Sinusitis

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ciclesonide

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ALV-020-001

P3

Completed

COVID-19

2021-01-05

Recent News Events